Diagnostyka i leczenia aterogennej dyslipidemii

• Autorzy: Szostak W B , Klosiewicz-Latoszek L. , Cybulska B.

Warianty tytułu

EN

Diagnosis and treatment of atherogenic dyslipidemia

• Języki publikacji: PL

Słowa kluczowe

PL

choroby dietopochodne; choroby czlowieka; statyny; dieta; diagnostyka; fibraty; dyslipidemia aterogenna

• Wydawca: -
• Czasopismo: Żywienie Człowieka i Metabolizm
• Rocznik: 2005
• Tom: 32
• Numer: 3
• Opis fizyczny: s.229-244,tab.,bibliogr.

Twórcy

autor

Szostak W B

• Instytut Zywnosci i Zywienia, Warszawa

autor

Klosiewicz-Latoszek L.

autor

Cybulska B.

Bibliografia

• 1. Alberti KGM., Zimmet PZ.: For the WHO Consultation: Definition, diagnosis and classification of diabetes mellitus and it's complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of WHO Consultation. Diabel. Med., 1998, 15, 539-553.
• 2. Athyros VG., Papageorgiu AA., Hatzikonstandiou HA. et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refactory familial combined hyperlipidemia. Am. J. Cardiol. 1997;80:608-13.
• 3. Austin MA, McKnight B, Edwards KL, et al.:. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. Circulation 2000;101:2777-82.- 4. Ballantyne CM., Corsini A., Davidson MH. et al.: Risk for myopathy with Statin therapy in high-risk patients. Arch. Intern. Med. 2003,163,553-64.
• 5. Brinton EA.: Lipid anormalities in the metabolic syndrome. Curr. Diabet. Rep. 2003,3,65-72 - 6. Busetto L.: Visceral obesity and the metabolic syndrome: effects of weight loss. Nutr. Metab. Cardiovasc. Dis. 2001, 11, 195- 204
• 7. Campbell ML., Mathys L.: Pharmacologic options for the treatment of obesity. Am. J. Health- Syst. Pharm. 2001,58(14), 1301-8.
• 8. Castelli WP: Epidemiology of triglycerides: a view from Framingham. Am. J. Cardiol.1992,70,3H- 9H.
• 9. Clinician's manual on hyperlipidaemia Ed. AM Gotto, LA Carlson, DR Illingworth, GR'Thompson, Current Science Ltd, London, 1990.
• 10. Cybulska C., Klosiewicz-Latoszek L.: Diagnostyka i leczenie hipercholesterolemii. Żyw. Czlow. Metab., 2005, 32, 2, 74.
• 11. CybulskaB., Szostak-Węgierek D., Szostak WB.: Ocena skuteczności bezpieczeństwa i tolerancji fenofibratu w postaci zmikronizowanej (Lipanthylu) w leczeniu hiperlipidemii mieszanej. Kardiol. Pol.1998, XLV, supl. III, 35-39
• 12. Diabetes Atheriosclerosis Intervention Study Investigators: Effect of fenofibrate on progression of coronary - artery disease in type 2 diabetes: the Diabetes Atheriosclerosis Intervention Study, a randomised study. Lancet 2001, 357, 905-910.
• 13. Downs JR, Clearfield M., Weis S., et al.: Primary prevention of acuite coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/texCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998;279:1615-1622.
• 14. Dunn FL, Grundy SM, Bilheimer DW, et al.: Impaired catabolism of very low-density lipoproteintriglyceride in a family with primary hypertriglyceridemia. Metab. 1985:34:735-50
• 15. East C., Bilheimer DW., Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann. Intern. Med. 1988;109:25-32.
• 16. Ellen RL., McPherson R.: Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am. J. Cardiol. 1998;81:60B-5B.
• 17. Farnier M., Picard S.: Diabetes: statins, fibrates, or both. Curr. Atheroscler. Rep. 2001,3,19-28. 18. Frick MH, Elo MO, Haapa K. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 1987:317:1237-45.
• 19. Fruchart J-C, Duriez.: HDL and trigliceride as therapeutic targets. Curr. Opin. Lipidol. 2002,13,605-16.
• 20. Gaede P., Vedel P, Larsen N. et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003,348,5,383-93.
• 21. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The CARE Investigators. Circulation. 1998, 98, 2513-2519.
• 22. Goldstein JL., Schrott HG., Hazzard WR., et al.: Hyperlipidaemia in coronary heart disease II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J. Clin. Invest. 1973,52,1544-68.
• 23. Grundy SM, Pasternak R, Greenland R et al.: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare profesionals from the American Heart Association and the American College of Cardiology. Circulation 1999:100:148-92.
• 24. Grundy SM. Hypertrigly- cerydemia, atherogenic dyslipidemia, and the metabolic syndrome. Am. J. Cardiol. 1998;8:18B-25 B.
• 25. Grzybek A., Stolarska J., Kłosiewicz-Latoszek L.: Hypolipemic diet introduced on the outpatient basis. The effect on lipid and lipoprotein serum levels. Kardiol. Pol. 2001,55,530-35.
• 26. Haffner SM., Alexander CM., Cook TJ. et al.: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch. Intern. Med. 1999;159:2661- 2667. 27. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year fllow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-77.
• 28. Idior-Walus B., Sieradzki J., Rostworski W. et al.: Effects of micronised fenofibrate on lipid and insulin sensitivity in patients with polimetabolic syndrome X. Eur. J. Clin. Invest. 2000,30,871-5.
• 29. Isomaa B., Algren P., Tuomi T., et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24, 683-689.
• 30. Kannel WB, Neaton JD, Wentwirth D, et al. for the MRFIT Research Group. Overal and coronary heart disease mortality rates in relation to major risk factors in 325 348 men screened for the MRFIT. Am. Heart. J. 1986;112:825-36.
• 31. Kłosiewicz-Latoszek L., Cybulska B.: Zespół metaboliczny. Zasady profilaktyki i leczenia. Kardiol. Pol., 2003, 59, 59-65.
• 32. Kłosiewicz-Latoszek L., Nowicka G., Grzybek A., et al.: Hypolipemic diet effect on lipoprotein profile in patients with hypercholesterolemia and mixed hyperlipidemia in relation to apoE phenotype. Medical Science. 1999,5(1), 62-70.
• 33. Kłosiewicz-Latoszek L., Respondek W., Paluszkiewicz J. et al.: Efektywność i bezpieczeństwo terapii skojarzonej statynami i fibratami w porównaniu z monoterapią u pacjentów z hiperlipidemią mieszaną i dużym ryzykiem choroby niedokrwiennej serca. Pol. Merk. Lek., 2003, 15, 85, 42- 46.
• 34. Kłosiewicz-Latoszek L., Szostak WB.: Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia. Eur. J. Clin. Pharm. 1991, 40, 30-41.
• 35. Kokkinos PF, Fernhall B. Physical activity and high density lippoprotein cholesterol levels: what is the relationship? Sports Med. 1999; 28:307-14.
• 36. Lakka H-M, Laaksonen DE, Lakka TA et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA,2002,288,2700-16.
• 37. Lardinois CK., Neuman SL. the effects of antihypertensive agents on serum lipids and lipoproteines. Arch. Intern. Med. 1988;148:1280-8.
• 38. Mahley RW, Rail S.C. Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL., Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease, 7th edition. New York: McGraw-Hill, 1995, 1953-80.
• 39. Martin MJ., Hulley SB., Brower WS. et al.: Serum cholesterol, blood pressure and mortality: implications from a cohort of 361 622 men. Lancet, 1986,ii,933-936.
• 40. MRC/BHF Heart Protection Study of cholesterol lowering with simwastatin in 20 536 high - risk individuals: a randomised placebo-controlled trial. Lancet, 2002,360,7-22.
• 41. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obesity Res. 1998:6(suppl 2):51S-209S. 42. Okopień B., Łebek M., Herman ZS.: Pleiotropowe działania fibratów. Pol. Arch. Med. Wew. 2001,CVI, 6(12) 1187-91.
• 43. Pasternak RC., Smith S.C., Bairey-Metz CN et al.: ACC/AHA/NHLBI Clinical Advisory on the use and safety of statins. Circulation, 2002, 106, 1024-1028.
• 44. Program Pol-MONICA Bis byłe województwo tarnobrzeskie. Stan zdrowia ludności byłego województwa tarnobrzeskiego w roku 32001. Cz. III. Podstawowe wyniki badania przekrojowego. Inst. Kardiologii, Warszawa 2002.
• 45. Program Pol-MONICA Bis Warszawa. Stan zdrowia ludności Warszawy w roku 2001. Cz. I. Podstawowe wyniki badania przekrojowego. Inst. Kardiologii, Warszawa 2002.
• 46. Pyorala K, Pedersen TR, Kjekshus J., et al.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997; 20:614- 620.
• 47. Ragucci E., Zomszein J., Frishman H.: Pharmacotherapy of diabetes mellitus implications for the prevention and treatment of cardiovascular disease. Heart Dis. 2003,5(1) 18-33.- 48. Rekomendacje Komisji Profilaktyki Polskiego Towarzystwa Kardiologicznego "Profilaktyka Choroby Niedokrwiennej Serca w Praktyce Klinicznej". Kardiol. Pol., 2000,53,supl.I-5 - 1-45.
• 49. Rubins HB., Robins SJ, Collins D., i wsp.: Diabetes plasma insulin and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High - Destiny - lipoprotein Intervention Trial (VA- HIT). Arch. Intern. Med., 2002, 162, 2597-2604.
• 50. Rużyłło E., Szostak WB., Cybulska B.: The influence of Clofibrate on glucose tolerance in patients with coronary heart disease. Pol. Arch. Med. Wew. 1972,49,2,121-123.
• 51. Sacks F.M., Appel L.J., Moore T.J., et al.: A dietary approach to prevent hypertension: a review of the Dietary Approaches to Stop Hypertension (DASH) Study. Clin. Cardiol. 1999, (Suppl. III), III6-III10.
• 52. Sowers JR.: Effect of statins on the vasculature: implications for aggressive lipid management in the cardiovascular metabolic syndrome. Am. J. Cardiol. 2003,91(suppl),14B-22B.
• 53. Strong Heart Study Investigators, Howard By Cowan LLD, Go on multiple cardiovascular disease risk factors in women. The Strong Heart Study. Diabetes Care 1998;21:1258-65.
• 54. Superko HR., Nejedly M., Garrett B.: Small LDL and its clinical importance as a new CAD risk factor: a female case study. Prog. Cardiovasc. Nurs 2002,17(4),167-173.
• 55. Takemoto M., Liao JK.: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler. Thromb. Vase. Biol. 2001, 21, 1712-1719.
• 56. Taskinen M-R.: Diabetic dyslipidemia. Atherosclerosis Supll. 2002, 3, 47-51.
• 57. The ILIB Lipid Handbook for Clinical Practice Ed. by A.M. Gotts et al.: International Lipid Information Bureau, New York, 2000
• 58. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998, 339, 1349-1357.
• 59. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Paneli III). Final Report. Circulation, 2002,106,3145-3420.
• 60. United Kingdom Prospective Diabetes Study Group, Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holmann RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS:23). Br. Med. J. 1998;316:823-8.
• 61. Vakkilainen J., Steiner G., Ansquer J-C., et al.: Relationships between low- density lipoprotein particle size plasma lipoproteins and progression of coronary artery disease. The Diabetes Altherosclerosis Intervention Study (DIAS). Circulation 2003, 107(13)1733-7.
• 62. Venkatesan S., Cullen P., Pacy P., et al.: Stable isotopes show a direct relation between VLDL apoB overproduction and serum trigliceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arteroscler. Thromb. 1993;13:1110-8.
• 63. Xydokis AM., Ballantyne CM.: Combination therapy for combined dyslipidemia. Am. J. Cardiol. 2002,90(supl) 21K-29K.
• 64. Yeshurun D., Abukarshin R., Elias N. et al. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination. Clin. Ther. 1993, 15, 355-63.